<div id="readability-page-1"><p><span>Celldex Therapeutics (NASDAQ:CLDX - Get Free Report)</span> had its price target boosted by equities research analysts at Barclays  from $21.00 to $24.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has an &#34;underweight&#34; rating on the biopharmaceutical company's stock. Barclays's price target points to a potential downside of 9.62% from the company's previous close.</p><div><p><span></span><span>Get <strong>Celldex Therapeutics</strong> alerts:</span></p></div><p>A number of other analysts also recently commented on the stock. Canaccord Genuity Group  reiterated a &#34;buy&#34; rating and issued a $62.00 target price on shares of Celldex Therapeutics in a report on Wednesday, September 17th. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Celldex Therapeutics in a research report on Wednesday, October 8th. HC Wainwright lowered their price target on shares of Celldex Therapeutics from $50.00 to $42.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, August 20th. Mizuho began coverage on shares of Celldex Therapeutics in a research report on Tuesday, October 21st. They set an &#34;outperform&#34; rating and a $48.00 target price for the company. Finally, Citigroup reduced their target price on shares of Celldex Therapeutics from $56.00 to $48.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, August 20th. One equities research analyst  has rated the stock with a Strong Buy rating, seven have given a Buy rating, one  has issued  a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock  has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $44.10.</p><p><b>View Our Latest Stock Analysis on Celldex Therapeutics</b></p><h2>Celldex Therapeutics Trading Down 0.5%</h2><p>NASDAQ CLDX traded down $0.13 on Wednesday, hitting $26.56. 190,756 shares of the stock traded hands, compared to its average volume of 993,017. The company has a market capitalization of $1.76 billion, a P/E ratio of -7.86 and a beta of 1.13. The stock has a 50-day moving average of $26.38 and a 200 day moving average of $24.00. Celldex Therapeutics has a twelve month low of $14.40 and a twelve month high of $30.50. </p><p>Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.13). Celldex Therapeutics had a negative return on equity of 33.22% and a negative net margin of 3,446.88%. As a group, equities research analysts expect that  Celldex Therapeutics will post -2.48 earnings per share for the current year. </p><h2>Insider Activity at Celldex Therapeutics</h2><p>In related news, insider Richard M. Wright sold 49,298 shares of the business's stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $24.00, for a total transaction of $1,183,152.00. Following the transaction, the insider directly owned 20,833 shares in the company, valued at approximately $499,992. The trade was a 70.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. 4.40% of the stock is currently owned by company insiders. </p><h2>Institutional Inflows and Outflows</h2><p>Institutional investors and hedge funds have recently modified their holdings of the stock. Aster Capital Management DIFC Ltd bought a new stake in shares of  Celldex Therapeutics in the third quarter worth about $26,000.  Nisa Investment Advisors LLC boosted its stake in  Celldex Therapeutics by 171.7% during the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 881 shares in the last quarter.  Wilmington Savings Fund Society FSB purchased a new stake in shares of  Celldex Therapeutics in the third quarter worth $42,000.  Russell Investments Group Ltd. raised its holdings in  Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company's stock worth $47,000 after buying an additional 501 shares during the last quarter.  Finally, Quantbot Technologies LP bought a new position in  Celldex Therapeutics during the third quarter valued at approximately $63,000. </p><h2>Celldex Therapeutics Company Profile</h2> (Get Free Report)<p>Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Celldex Therapeutics</li><li>Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?</li><li>Intel Snaps Up AI Tech for Pennies on the Dollar</li><li>The 3 Best Blue-Chip Stocks to Buy Now</li><li>4 Quantum Stocks to Watch as the Next Computing Revolution Unfolds</li><li>Quiet Period Expirations Explained</li><li>Massive Breakout in Industrials: 3 Must-Watch Stocks Now</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xEWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xEWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Celldex Therapeutics Right Now?</h2><p>Before you consider Celldex Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.</p><p>While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CLDX

<p>Barclays raised the price target for Celldex Therapeutics (NASDAQ:CLDX) from $21.00 to $24.00, maintaining an "underweight" rating. The new target suggests a potential downside of 9.62% from the previous close. Other analysts have mixed ratings, with a consensus rating of "Moderate Buy" and a target price of $44.10. Celldex recently reported a quarterly loss and insider Richard M. Wright sold shares. Institutional investors have adjusted their holdings in the company.</p>

Celldex Therapeutics (NASDAQ:CLDX) Price Target Raised to $24.00 at Barclays